Loading
A phase 2 trial of Masofaniten and Enzalutamide in Metastatic hormone-sensitive prostate cancer and Prostate cancer, run by Pedro Barata, MD, MSc, completed.
Combining EPI-7386 With Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer is a phase 2 interventional study registered as NCT06312670 by Pedro Barata, MD, MSc, with 13 participants recorded, started 2024-05-16 and reaching its primary completion in 2025-01-09. Interventions recorded: EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT). Conditions recorded: Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma.
Linked to the drug Masofaniten because the registry names it among its interventions and Metastatic hormone-sensitive prostate cancer and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Prostate cancer and the tag pipeline.
Shares Metastatic hormone-sensitive prostate cancer, Prostate cancer and the tag pipeline.
Shares Enzalutamide, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.